GILD250509C118000
- 0.24
- 0.000.00%
Gilead Sciences Newsroom
Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator
Express News | Gilead's Bulevirtide Shows Durability In Chronic HDV, With 90% of Patients on Long-Term Therapy Maintaining Undetectable HDV RNA Off-Treatment
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Gilead Sciences Down Nearly 5%, On Track for Largest Percent Decrease Since January 2024 -- Data Talk
Unusual Options Activity: SN, GILD and Others Attract Market Bets, SN V/OI Ratio Reaches 253.5
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $110
TD Cowen Keeps Their Buy Rating on Gilead Sciences (GILD)
Argus Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $120
These Are the Sectors Best Liked Within Defensive and Cyclicals Groups – Morgan Stanley
Express News | Gilead : Mizuho Raises Target Price to $117 From $100
Notable Healthcare Headlines for the Week: Gilead, CVS Health, Sanofi in Focus
Gilead and Vertex Pharma Named Among Biotech's Tariff Safe Havens
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $117
Gilead Sciences (GILD) Gets a Buy From Mizuho Securities
Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110
30 U.S. Picks Based on Up Vs. Down EPS Revisions and Dividend Payouts
10 Stocks Defying Wall Street Turbulence to Kick off the Month of May
Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest
Gilead Sciences: Hold Rating Maintained Amid Near-Term Challenges and Limited Growth Prospects
Gilead Sciences to Present at Upcoming Investor Conferences